Clinical Trials Sponsored by Mitsubishi Tanabe Pharma Corporation

Total 193 results

Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Diffuse Large B-Cell Lymphoma

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1-Associated Myelopathy (HAM)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Japanese Patients With ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Non-dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Healthy Adult Males

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Taiwan, Korea, Republic of, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Pediatric Ulcerative Colitis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

NASH

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

Healthy

Australia, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Terminated

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Acute Ischemic Stroke

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Chronic Kidney Disease | Hyperphosphatemia

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

Vasomotor Symptoms

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of MP-424

Chronic Hepatitis C

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MT-4666

Alzheimer's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Chronic Kidney Disease

Belarus, Bulgaria, Romania, Malaysia, Singapore, Thailand, Italy, Lithuania, Latvia, Croatia, Denmark, Israel, Indonesia
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

Crohn's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

Dyslipidemia

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Coronary Artery Disease | Angina, Unstable

Belgium, Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Type 2 Diabetes
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Diabetic Polyneuropathy
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Peripheral Vascular Disease

United States, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Terminated

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Peripheral Vascular Disease

United States, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Recruiting

An Exploratory Study of MT-2990 in Patients With AAV

Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Healthy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

ALS

Japan

3

Subscribe